We look for and find great opportunities
Blackhawk Growth Corp. is an investment issuer looking to capitalize on market and industry trends that can create substantial value for its shareholders. We look for opportunities all over the globe where we can leverage our knowledge, expertise, and experience to deliver substantial growth for our companies and our investors.
Blackhawk drives its growth by investing in equity and debt instruments of companies and generating positive returns with minimal risk for shareholders. The company’s strategy is focused on investing in multiple companies across a variety of sectors across North America.
Blackhawk signed a definitive agreement with Medigen Biotechnology Corporation and TBG Biotechnology Corp. to distribute certain diagnostic products, including an ExProbe SARS-CoV-2 Testing Kit and a SARS-CoV-2 IgG/IgM Rapid Test Kit used in the detection of antibodies associated with COVID-19. Both testing kits are EUA approved by the FDA.
Vancouver, British Columbia - TheNewswire - September 14, 2020 - Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (the "Corporation" or "Blackhawk"), is pleased to provide the following corporate updates. As of September 3rd, 2020, it has received a signed letter of authorization confirming that Blackhawk is the sole entity that possesses non-exclusive rights to distribute the SARS-CoV-2 IgG/IgM Rapid Test Kit…
Vancouver, British Columbia - TheNewswire - September 11, 2020 - Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (the "Corporation" or "Blackhawk") announces that despite inquiries made to Emergence Technology Pty. Ltd. ("Emergence") it has been unable to verify the nature of statements made by Innovita (Tangshan) Biological Technology Co. Ltd. ("Innovita") surrounding authorization for the distribution of the 2019-nCoV Ab Test Kit…